ClinicalTrials.gg
CompletedNCT01950247Updated May 22, 2025Results posted

Evaluate the Utility of Serum Hepcidin Levels to Predict Response to Oral or IV Iron

A Phase 4 interventional study of Injectafer and SOC in Iron Deficiency Anemia (IDA), sponsored by American Regent, Inc.. Completed. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-05-22.

Sponsored by American Regent, Inc. (part of Daiichi Sankyo) · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
1,025
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 57 studies testing ferric carboxymaltose in Anemia, Iron-Deficiency — 7 open to participants now, 7 under way, none of them phase 3. ferric carboxymaltose · Anemia, Iron-Deficiency.

Enrollment
5th of 57
1,025 · median 100
Started
2013
the only one that year
Phase 4
24 of 57
6 open now
Registered
16th of 57
by date
Lead sponsor
11 of 57
American Regent, Inc.

Among the 57 studies testing ferric carboxymaltose in Anemia, Iron-Deficiency, this one is the 5th largest by enrollment, is the only one that started in 2013, is one of 24 in phase 4, and was the 16th registered.

Anemia, Iron-Deficiency

601 studies on the registry are indexed under Anemia, Iron-Deficiency; 96 are open to participants now.

Browse Anemia, Iron-Deficiency studies →

Open to participants now

7 of the 57 studies testing ferric carboxymaltose in Anemia, Iron-Deficiency are open now, in 1 country. Recruiting first, the newest first:

2 more — sign in →

By country, each count listing its studies:

All 7 open studies →

About ferric carboxymaltose

ferric carboxymaltose: first FDA approval 2013 (INJECTAFER). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 55 Anemia, Iron-Deficiency studies recruiting now, 19 (35%) set no upper age limit and 32 (58%) stop at 75 or younger; 16 take children under 18; 17 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 57 studies testing ferric carboxymaltose in Anemia, Iron-Deficiency, or all of them as a file.
02

Study summary

The main objective of this study is to compare the safety, effect on quality of life, and resource utilization of Injectafer vs. intravenous (IV) iron standard of care (SOC) for the treatment of iron deficiency anemia (IDA) in an infusion center setting. The study will also assess the ability of baseline serum hepcidin levels to predict if subjects will have a clinically meaningful hemoglobin response to oral iron therapy or to IV iron therapy.

Read the detailed description

The main objective of this study is to compare the safety, effect on quality of life, and resource utilization of Injectafer vs. intravenous (IV) iron standard of care (SOC) for the treatment of iron deficiency anemia (IDA) in an infusion center setting. The study will also assess the ability of baseline serum hepcidin levels to predict if subjects will have a clinically meaningful hemoglobin response to oral iron therapy for 28 days or to IV iron therapy.

03

Conditions studied

  • Iron Deficiency Anemia (IDA)
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female subjects ≥ 18 years of age and able to give .
  • Iron deficiency is the primary etiology of anemia.
  • If using erythropoiesis stimulating agent (ESA), the subject must be using a dose consistent with package insert that has been stable for at least 30 days.
  • Doses of potential myelosuppressive medications have been stable for at least 30 days.
  • Females at risk of pregnancy must agree to use an acceptable form of and have a negative serum or urine pregnancy test on the first day of dosing.

Exclusion criteria

Exclusion Criteria:

  • reaction to any component of Injectafer.
  • Requires dialysis for treatment of chronic kidney disease (CKD).
  • No evidence of iron deficiency.
  • During the 10 day period prior to screening has been treated with intravenous iron.
  • During the 30 day period prior to screening has been treated with a red red blood cell transfusion.
  • Any non-viral infection.
  • Known positive hepatitis with evidence of active disease.
  • Received an drug within 30 days of screening.
  • Alcohol or drug abuse within the past 6 months.
  • Hemochromatosis or other iron storage disorders.
  • Estimated of less than 6 months, or for cancer patients, an (ECOG) Performance Status greater than 1.
  • Pregnant or actively trying to become pregnant (a definitive negative result on a serum or urine pregnancy test performed on the first day of dosing will be required for study enrollment by any women of ).
  • Any other laboratory abnormality, medical condition or psychiatric disorders which in the opinion of the investigator would put the subject's disease management at risk or may result in the subject being unable to comply with study requirements.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
1,025 participants (actual)

Study arms

  • Experimental
    Injectafer

    2 doses at 15 mg/kg for a maximum single dose of 750 mg given 7 days apart for a total of up to 1500 mg.

    Drug: Injectafer

  • Active comparator
    IV Iron Standard of Care (SOC)

    At a dose and administration regimen as determined by the study site investigator

    Drug: SOC

Interventions

  • 2 doses at 15 mg/kg for a maximum single dose of 750 mg given 7 days apart for a total of up to 1500 mg.

    Also known as: Ferric Carboxymaltose (FCM)

  • DrugSOC

    Also known as: IV Iron Standard of Care

06

What researchers measure

Primary outcomes

  1. Multidimensional Assessment of Fatigue (MAF) Scores

    The MAF scale has 16 items that measure the Global Fatigue Index (GFI), a composite score of Items 1 through 15. Items 1 through 14 were measured on a scale of 1 to 10, with 1 = not at all and 10 = a great deal. Items 15 and 16 had categorical responses: degree of agreement from 0 to 4, with 0=no days and 4=every day. Then, a Global Fatigue Index (GFI) is calculated by summing specific items and averaging others. The final GFI score ranges from 1 (no fatigue) to 50 (severe fatigue). The resulting score is given as the mean value.

    Time frame: Baseline to Day 30

  2. Work Productivity and Activity Impairment Questionnaire (WPAI) Scores

    The WPAI consisted of six questions: 1 = currently employed; 2 = hours missed due to health problems; 3 = hours missed other reasons; 4 = hours actually worked; 5 = degree health affected productivity while working using a scale of 0 to 10, with 0 = PROBLEM had no effect on my work and 10 = PROBLEM completely prevented me from working; 6 = degree health affected productivity in regular unpaid activities using a scale of 0 to 10, with 0 = PROBLEM had no effect on my daily activities and 10 = PROBLEM completely prevented me from doing my daily activities. It yields 4 sub-scores: work time missed (absenteeism), impairment while working (presenteeism or reduced on-the-job effectiveness), overall work impairment (work productivity loss or absenteeism plus presenteeism) and activity impairment (daily activity impairment). These sub-scores are transformed to impairment percentages (range from 0 to 100), with higher numbers indicating greater impairment and less productivity.

    Time frame: Baseline and Day 30

  3. Treatment Satisfaction Questionnaire for Medication Version 1.4 Scores

    Participants rated 14 items with 4 domains. Scores for item 1 to 3, 9 to 11 and 14 ranged from 1=extremely dissatisfied to 7=extremely satisfied. Items 5 to 8, 12, 13 ranged from 1=extremely dissatisfied to 5=not at all dissatisfied. Item 4 was scored as: 0=No, 1=Yes. Effectiveness measured as (\[{sum of item 1 to 3} - 3\]/18)\*100; if 1 question (Q) was missing: (\[{sum of item 1 to 3} -2\]/12)\*100. Side-effect measured as if item 4=No, score=100; if not then (\[{sum of item 5 to 8} -4\]/16)\*100; if 1 Q was missing: (\[{sum of item 5 to 8} -3\]/12)\*100. Convenience measured as (\[{sum of item 9 to 11} -3\]/18)\*100; if 1 Q was missing: (\[{sum of item 9 to 11} - 2\]/12)\*100. Global satisfaction as (\[{sum of item 12 to 14} -3\]/14)\*100; if item 12 or 13 was missing: (\[{sum of item 12 to 14} -2\]/10)\*100; if item 14 was missing: (\[{sum of item 12 and 13} -2\]/8)\*100. All domains had scale of 0 (no satisfaction) to 100 (best level of satisfaction), higher score equals greater satisfaction

    Time frame: Baseline and Day 30

  4. Short Form Health Survey, 12-Item (SF-12) v2 Quality of Life Scores.

    The SF-12 is a multipurpose short form to measure health status. There are 10 domains: Physical Composite Index (score range from 0-100); Physical Functioning Index (score range from 0-100); Role Limitation Physical Index (score range 0-100); Pain Index Score (score range from 0-100); General Health Index (score range from 0-100); Mental Health Composite Index (score range from 1-100); Vitality Index (score range from 0-100); Social Functioning Index (score rang 0-100); Role Limitation Emotional Index (score range 0-100); and SF-12 Mental Health Index (score range from 0-100), the higher the score means a better outcome. The overall scale and sub-scales were calculated with the standard SF-12 formulas.

    Time frame: Baseline and Day 30

07

Results

Posted May 22, 2025

Participant flow

Participant flow — Overall Study
MilestoneIV Iron Standard of Care (SOC)Injectafer
Started512513
Completed455467
Not completed5746
Withdrew: Withdrawal by subject2813
Withdrew: Lost to follow-up1816
Withdrew: Physician decision34
Withdrew: Adverse event32
Withdrew: Death11
Withdrew: Not defined410

Outcome measures

PrimaryMultidimensional Assessment of Fatigue (MAF) Scores

The MAF scale has 16 items that measure the Global Fatigue Index (GFI), a composite score of Items 1 through 15. Items 1 through 14 were measured on a scale of 1 to 10, with 1 = not at all and 10 = a great deal. Items 15 and 16 had categorical responses: degree of agreement from 0 to 4, with 0=no days and 4=every day. Then, a Global Fatigue Index (GFI) is calculated by summing specific items and averaging others. The final GFI score ranges from 1 (no fatigue) to 50 (severe fatigue). The resulting score is given as the mean value.

Time frame:
Baseline to Day 30
Reported as:
Mean · units on a scale
Multidimensional Assessment of Fatigue (MAF) Scores
units on a scaleInjectaferIV Iron Standard of Care (SOC)
Multidimensional Assessment of Fatigue (MAF) Scores-8.8 ± 11.38-8.1 ± 11.28
PrimaryWork Productivity and Activity Impairment Questionnaire (WPAI) Scores

The WPAI consisted of six questions: 1 = currently employed; 2 = hours missed due to health problems; 3 = hours missed other reasons; 4 = hours actually worked; 5 = degree health affected productivity while working using a scale of 0 to 10, with 0 = PROBLEM had no effect on my work and 10 = PROBLEM completely prevented me from working; 6 = degree health affected productivity in regular unpaid activities using a scale of 0 to 10, with 0 = PROBLEM had no effect on my daily activities and 10 = PROBLEM completely prevented me from doing my daily activities. It yields 4 sub-scores: work time missed (absenteeism), impairment while working (presenteeism or reduced on-the-job effectiveness), overall work impairment (work productivity loss or absenteeism plus presenteeism) and activity impairment (daily activity impairment). These sub-scores are transformed to impairment percentages (range from 0 to 100), with higher numbers indicating greater impairment and less productivity.

Time frame:
Baseline and Day 30
Reported as:
Mean · units on a scale
Work Productivity and Activity Impairment Questionnaire (WPAI) Scores
units on a scaleInjectaferIV Iron Standard of Care (SOC)
Percent activity impairment due to problem-15.2 ± 29.85-11.5 ± 29.43
Percent impairment while working due to problem-13.2 ± 28.75-8.5 ± 24.44
Percent overall work impairment due to problem-13.4 ± 31.66-8.5 ± 25.89
Percent work time missed due to problem-3.2 ± 23.76-2.5 ± 17.23
PrimaryTreatment Satisfaction Questionnaire for Medication Version 1.4 Scores

Participants rated 14 items with 4 domains. Scores for item 1 to 3, 9 to 11 and 14 ranged from 1=extremely dissatisfied to 7=extremely satisfied. Items 5 to 8, 12, 13 ranged from 1=extremely dissatisfied to 5=not at all dissatisfied. Item 4 was scored as: 0=No, 1=Yes. Effectiveness measured as (\[{sum of item 1 to 3} - 3\]/18)\*100; if 1 question (Q) was missing: (\[{sum of item 1 to 3} -2\]/12)\*100. Side-effect measured as if item 4=No, score=100; if not then (\[{sum of item 5 to 8} -4\]/16)\*100; if 1 Q was missing: (\[{sum of item 5 to 8} -3\]/12)\*100. Convenience measured as (\[{sum of item 9 to 11} -3\]/18)\*100; if 1 Q was missing: (\[{sum of item 9 to 11} - 2\]/12)\*100. Global satisfaction as (\[{sum of item 12 to 14} -3\]/14)\*100; if item 12 or 13 was missing: (\[{sum of item 12 to 14} -2\]/10)\*100; if item 14 was missing: (\[{sum of item 12 and 13} -2\]/8)\*100. All domains had scale of 0 (no satisfaction) to 100 (best level of satisfaction), higher score equals greater satisfaction

Time frame:
Baseline and Day 30
Reported as:
Mean · units on a scale
Treatment Satisfaction Questionnaire for Medication Version 1.4 Scores
units on a scaleInjectaferIV Iron Standard of Care (SOC)
Overall Satisfaction72.6 ± 25.0372.7 ± 21.07
Effectiveness69.3 ± 22.3866.5 ± 21.75
Side Effects63.5 ± 27.2169.2 ± 21.00
Convenience78.9 ± 17.3172.8 ± 20.00
PrimaryShort Form Health Survey, 12-Item (SF-12) v2 Quality of Life Scores.

The SF-12 is a multipurpose short form to measure health status. There are 10 domains: Physical Composite Index (score range from 0-100); Physical Functioning Index (score range from 0-100); Role Limitation Physical Index (score range 0-100); Pain Index Score (score range from 0-100); General Health Index (score range from 0-100); Mental Health Composite Index (score range from 1-100); Vitality Index (score range from 0-100); Social Functioning Index (score rang 0-100); Role Limitation Emotional Index (score range 0-100); and SF-12 Mental Health Index (score range from 0-100), the higher the score means a better outcome. The overall scale and sub-scales were calculated with the standard SF-12 formulas.

Time frame:
Baseline and Day 30
Reported as:
Mean · units on a scale
Short Form Health Survey, 12-Item (SF-12) v2 Quality of Life Scores.
units on a scaleInjectaferIV Iron Standard of Care (SOC)
Pain1.6 ± 10.032.5 ± 10.52
Overall Physical Health Score3.3 ± 7.943.1 ± 8.33
Overall Mental Health Score3.7 ± 10.313.7 ± 10.39
Physical Functioning3.6 ± 10.423.4 ± 10.45
Role Limitation Physical4.0 ± 9.533.9 ± 9.25
General Health3.2 ± 9.862.5 ± 9.84
Vitality7.7 ± 11.367.0 ± 11.53
Social Functioning3.6 ± 12.193.0 ± 11.47
Role Limitation Emotion2.7 ± 12.692.8 ± 12.62
Mental Health2.9 ± 10.103.3 ± 9.62

Adverse events

Collected over Day 1 to Day 30. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Injectafer1/513 (0.2%)4/513 (0.8%)28/513 (5.5%)
IV Iron Standard of Care (SOC)1/512 (0.2%)1/512 (0.2%)21/512 (4.1%)
Most frequent serious events
Most frequent serious events
EventInjectaferIV Iron Standard of Care (SOC)
Cardiac disordersCardiac disorders4/5131/512
Most frequent other events
Most frequent other events
EventInjectaferIV Iron Standard of Care (SOC)
NauseaGastrointestinal disorders28/51321/512

Baseline characteristics

Age, Continuous
Age, Continuous(years)InjectaferIV Iron Standard of Care (SOC)Total
Mean57.2 ± 16.5855.7 ± 16.6856.5 ± 16.64
Sex: Female, Male
Sex: Female, Male(Participants)InjectaferIV Iron Standard of Care (SOC)Total
Female421409830
Male92103195
Region of Enrollment
Region of Enrollment(Participants)InjectaferIV Iron Standard of Care (SOC)Total
United States5135121025
08

Study locations

No study locations are listed for this record.

09

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2013 to primary completion in May 2015, 21 months.

Results were first posted in May 2025, 10 years after primary completion.

Of 51 phase 4 interventional studies under Anemia, Iron-Deficiency, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 35. This study's 21 months is close to that.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 23, 2013
First posted
Sep 25, 2013
StartActual
Aug 15, 2013
Primary completionActual
May 20, 2015
CompletionActual
Jun 2015
Results first posted
May 22, 2025
Last update
May 22, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 22, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01950247
Responsible party
Sponsor
First posted
Sep 25, 2013
Start date
Aug 15, 2013
Primary completion
May 20, 2015
Completion
Jun 2015
Results posted
May 22, 2025
Last update
May 22, 2025

Study contacts

Mark Falone, MD
study director · American Regent, Inc.

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ferric carboxymaltose

Start the discussion